The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Net income | 1,046 | 921 | 908 | 1,015 |
| Depreciation and amortization | 570 | 493 | 439 | 437 |
| Provision for credit losses | 3 | 5 | 1 | 3 |
| Deferred income tax provision (benefit) | 105 | 13 | -49 | 1 |
| Stock-based compensation expense | 88 | 88 | 77 | 77 |
| Gain on disposition of joint venture | - | - | 0 | 0 |
| Other, net | -24 | -15 | -41 | -66 |
| Accounts receivable | 106 | 71 | 15 | -246 |
| Accounts payable and accrued expenses | 129 | -67 | -55 | -149 |
| Income taxes payable | 24 | 16 | -2 | -31 |
| Termination of interest rate swap agreements | - | - | - | 0 |
| Other assets and liabilities, net | -3 | 79 | 73 | -53 |
| Net cash provided by operating activities | 1,886 | 1,334 | 1,272 | 1,718 |
| Business acquisitions, net of cash acquired | 101 | 2,164 | 611 | 144 |
| Proceeds from disposition of joint venture | - | - | 0 | 0 |
| Capital expenditures | 527 | 425 | 408 | 404 |
| Other investing activities, net | 3 | -41 | 42 | -5 |
| Net cash used in investing activities | -631 | -2,548 | -1,061 | -543 |
| Proceeds from borrowings | 410 | 1,846 | 2,592 | 0 |
| Repayments of debt | 1,012 | 303 | 1,844 | 2 |
| Purchases of treasury stock | 450 | 151 | 275 | 1,408 |
| Exercise of stock options | 79 | 73 | 72 | 123 |
| Employee payroll tax withholdings on stock issued under stock-based compensation plans | 45 | 24 | 28 | 28 |
| Dividends paid | 353 | 331 | 314 | 305 |
| Distributions to noncontrolling interest partners | 56 | 47 | 57 | 73 |
| Other financing activities, net | 39 | 21 | 14 | -39 |
| Net cash (used in) provided by financing activities | -1,388 | 1,084 | 160 | -1,732 |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | 4 | -7 | - | - |
| Net change in cash and cash equivalents and restricted cash | -129 | -137 | 371 | -557 |
| Cash and cash equivalents and restricted cash, beginning of year | 549 | 686 | 315 | 872 |
| Cash and cash equivalents and restricted cash, end of year | 420 | 549 | 686 | 315 |
QUEST DIAGNOSTICS INC (DGX)
QUEST DIAGNOSTICS INC (DGX)